Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

INTRODUCTION: Autologous T-cells transduced to express a chimeric antigen receptor (CAR) directed against CD19 elicit high response rates in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). However, r/r B-NHL remissions are durable in fewer than half of recipients of second-generati...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Philip, Dasyam, Nathaniel, Giunti, Giulia, Mester, Brigitta, Bauer, Evelyn, Andrews, Bethany, Perera, Travis, Ostapowicz, Tess, Frampton, Chris, Li, Peng, Ritchie, David, Bollard, Catherine M, Hermans, Ian F, Weinkove, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044946/
https://www.ncbi.nlm.nih.gov/pubmed/32041862
http://dx.doi.org/10.1136/bmjopen-2019-034629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044946/
https://www.ncbi.nlm.nih.gov/pubmed/32041862
http://dx.doi.org/10.1136/bmjopen-2019-034629

Ejemplares similares